BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BNTX BioNTech SE

交易中 03-25 14:07:34 EDT

88.79

+1.98

+2.28%

最高89.17	最低87.76	成交量31.09万
今开88.00	昨收86.81	日振幅1.62%
总市值222.85亿	流通市值93.22亿	总股本2.51亿
成交额2,757万	换手率0.30%	流通股本1.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BNTX","market":"US","secType":"STK","nameCN":"BioNTech SE","latestPrice":88.785,"timestamp":1774462052013,"preClose":86.81,"halted":0,"volume":310874,"delay":0,"changeRate":0.022750835157239885,"floatShares":105000000,"shares":250999999,"eps":-5.518909,"marketStatus":"交易中","change":1.975,"latestTime":"03-25 14:07:34 EDT","open":88,"high":89.17,"low":87.76,"amount":27568296.99378,"amplitude":0.016242,"askPrice":88.87,"askSize":40,"bidPrice":88.76,"bidSize":36,"shortable":3,"etf":0,"ttmEps":-5.518909,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1774468800000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1570680000000,"exchange":"NASDAQ","adjPreClose":86.81,"preHourTrading":{"tag":"盘前","latestPrice":87.99,"preClose":86.81,"latestTime":"09:29 EDT","volume":6306,"amount":554247.83484,"timestamp":1774445399999,"change":1.18,"changeRate":0.013593,"amplitude":0.015206},"postHourTrading":{"tag":"盘后","latestPrice":87.06,"preClose":86.81,"latestTime":"19:59 EDT","volume":57789,"amount":5016849.68,"timestamp":1774396798065,"change":0.25,"changeRate":0.00288,"amplitude":0.00288},"volumeRatio":0.318535,"impliedVol":0.4695,"impliedVolPercentile":0.6175},"requestUrl":"/m/hq/s/BNTX","defaultTab":"news","newsList":[{"id":"2618940472","title":"BioNTech创始人将离职创立新的mRNA企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940472","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618940472?lang=zh_cn&edition=full","pubTime":"2026-03-11 21:11","pubTimestamp":1773234660,"startTime":"0","endTime":"0","summary":"BioNTech （BNTX）表示，联合创始人乌古尔·萨欣和厄兹莱姆·图雷齐将离职创办一家专注于mRNA的新公司，BioNTech将持有少数股权并提供某些技术授权。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-11/doc-inhqrrth2401842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BNTX","BK4535","BK4548","BK4551","BK4568","SINA","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2618951995","title":"美股异动 | 2026年收入指引低于预期 BioNTech(BNTX.US)暴跌超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618951995","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618951995?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:46","pubTimestamp":1773153966,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，BioNTech盘初暴跌超20%，创4月25日以来最大跌幅，现报80.20美元。消息面上，此前该公司公布的第四季度调整后亏损以及2026年全年收入指引均低于分析师的预期。公司报告称，第四季度每股稀释后调整亏损为0.33欧元，而一年前每股盈利为1.79欧元，FactSet调查的分析师预计每股亏损为0.16欧元。对于2026年，该公司表示预计收入将在20亿欧元至23亿欧元之间，FactSet调查的分析师预计收入为27.5亿欧元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"55e023d8b9b1e3375a9483dab88b04b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","BK4551","BK4535","BNTX","BK4568","BK4588","BK4548","BK4139"],"gpt_icon":0},{"id":"1191971117","title":"异动解读 | 创始人离职叠加业绩指引下调，BioNTech盘中暴跌21.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191971117","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191971117?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:45","pubTimestamp":1773150305,"startTime":"0","endTime":"0","summary":"BioNTech SE (BNTX) 今日盘中股价大幅下挫21.54%，引发了市场的广泛关注。消息面上，公司联合创始人兼核心领导层Ugur Sahin和Oezlem Tuereci宣布将于2026年底离开公司，以创立自己的新企业。这一关键人事变动引发了投资者对公司未来战略连续性与管理层稳定性的深度担忧，被认为是冲击股价的首要因素。与此同时，公司发布的第四季度财务报告显示营收同比下滑，净亏损扩大。更为关键的是，公司下调了2026年全年业绩指引，预计总收入为20亿至23亿欧元，远低于市场此前27.5亿欧元的预期。黯淡的财务前景与盈利挑战进一步加剧了市场的抛售情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"55e023d8b9b1e3375a9483dab88b04b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BNTX"],"gpt_icon":0},{"id":"1141487455","title":"美股盘前｜蔚来涨超6%，BNTX大跌16%；特朗普称有可能有条件同伊朗谈判；SpaceX倾向赴纳斯达克进行IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1141487455","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141487455?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:09","pubTimestamp":1773144598,"startTime":"0","endTime":"0","summary":"摘要：特朗普称有可能有条件同伊朗谈判SpaceX倾向赴纳斯达克进行IPO，将提前纳入纳斯达克100指数作为条件首次季度盈利！其中两位消息人士称，SpaceX将提前纳入纳斯达克100指数作为在这家科技股交易所上市的必要条件。据路透此前报道，SpaceX计划最早于今年6月进行IPO。","market":"us","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"55e023d8b9b1e3375a9483dab88b04b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4509","BK4548","BK4574","BK4531","BK4585","BK4099",".DJI","BK1588","LU0052750758.USD","BK4588","BK4526","BNTX",".IXIC",".SPX","NIO","LU0320764599.SGD","BK4555","BK4504","BK4581","LU0708995583.HKD","BK6125","BK1119","BK4534","BK4532","BK4505"],"gpt_icon":1},{"id":"1113795355","title":"BioNTech创始人夫妇萨欣与图雷吉将离职成立新公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1113795355","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113795355?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:02","pubTimestamp":1773140536,"startTime":"0","endTime":"0","summary":"生物技术公司BioNTech周二表示，其联合创始人Ugur Sahin和Oezlem Tuereci将于2026年底前离开这家新冠疫苗制造商，以创立他们自己的新公司。公司在一份声明中表示：“BioNTech监事会已启动高管遴选程序，以确定继任者人选，从而确保平稳过渡，并保证BioNTech战略能够持续、顺畅地执行。”BioNTech盘前跌逾14%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/c13b15b77fdb00714b0cdfb36ef3c9ad","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/c13b15b77fdb00714b0cdfb36ef3c9ad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e97184404937945405da3423e523494d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"gpt_icon":0},{"id":"1168969614","title":"BioNTech全年每股亏损4.7欧元 营收超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1168969614","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168969614?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:57","pubTimestamp":1773140253,"startTime":"0","endTime":"0","summary":"BioNTech SE公布的最新财务数据显示，其全年营收达到28.699亿欧元，显著超越市场预期。此前，机构IBES对其营收的预估值为27.37亿欧元。然而，在营收表现亮眼的同时，公司全年每股收益为负4.7欧元，表明其盈利能力面临挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4551","BK4139","BK4568","BK4588","BK4585","BNTX","BK4548"],"gpt_icon":0},{"id":"1180026932","title":"异动解读 | BioNTech创始夫妇宣布离职，股价盘前大跌14.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180026932","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180026932?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:52","pubTimestamp":1773139963,"startTime":"0","endTime":"0","summary":"BioNTech SE (BNTX) 今日盘前股价大幅下挫14.84%，引发了市场的高度关注。消息面上，BioNTech的联合创始人兼核心领导层Ugur Sahin和Oezlem Tuereci宣布将于2026年底离开公司，以成立自己的新公司。这一关键人事变动引发了投资者对公司未来战略连续性和管理层稳定性的担忧，被认为是导致股价急跌的主要原因。根据公司声明，BioNTech监事会已开始物色继任者，以确保平稳过渡。Sahin和Tuereci作为公司的灵魂人物，其离职决定无疑给市场带来了不确定性，并可能影响投资者对公司长期发展前景的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e97184404937945405da3423e523494d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BNTX"],"gpt_icon":0},{"id":"1120337490","title":"BioNTech SE四季度营收同比下滑，预计2026年总收入不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1120337490","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120337490?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:51","pubTimestamp":1773139900,"startTime":"0","endTime":"0","summary":"3月10日，BioNTech SE暴跌逾15%！预计2026年总收入为20亿至23亿欧元，不及预期。","market":"us","thumbnail":"https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1a848e5e265147d0872d15bef61ff0d3","theme_name":"热榜No.3 · 2025 Q4财报：拼多多四季度调整后每ADS收益17.69元低于预估","theme_type":2,"isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioNTech SE四季度营收同比下滑，预计2026年总收入不及预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"gpt_icon":0},{"id":"1167701131","title":"BioNTech将于2026年3月10日公布2025年第四季度及全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1167701131","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167701131?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:50","pubTimestamp":1771933815,"startTime":"0","endTime":"0","summary":"德国美因茨，2026年2月24日——BioNTech SE将于2026年3月10日星期二发布其2025年第四季度及全年的财务业绩。同日，公司将于美国东部时间上午8:00举行电话会议和网络直播，面向投资者、财务分析师及公众讨论财务业绩并提供公司最新动态。BioNTech是一家全球性的新一代免疫疗法公司，致力于开发针对癌症及其他重大疾病的新型研究性疗法。更多信息请访问www.BioNTech.com。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK4548","BK4535","BK4588","BNTX","CAR","BK4139","BK4585","BK4568","BK4022","BK4551"],"gpt_icon":0},{"id":"2612287922","title":"BioNTech控告Moderna侵犯新冠疫苗专利","url":"https://stock-news.laohu8.com/highlight/detail?id=2612287922","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612287922?lang=zh_cn&edition=full","pubTime":"2026-02-20 03:26","pubTimestamp":1771529160,"startTime":"0","endTime":"0","summary":"德国生物制药公司BioNTech周四在特拉华州联邦法院起诉Moderna，指控Moderna的新冠疫苗 mNEXSPIKE侵犯了BioNTech和辉瑞公司的竞争性疫苗Comirnaty的相关专利。　　该诉讼称，Moderna公司于2025年获得美国食品药品管理局批准的下一代新冠疫苗mNEXSPIKE，侵犯了BioNTech公司在用于简化mRNA疫苗设计的技术方面的权利，该技术允许以较低剂量为患者接种。　　Moderna在2022年起诉BioNTech及其合作伙伴辉瑞公司侵犯了Comirnaty的专利权，目前诉讼仍在进行中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-20/doc-inhnkyhw6558658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MRNA","BNTX","MRNX","MRNY"],"gpt_icon":1},{"id":"1133871627","title":"Leerink Partners下调BioNTech SE评级至\"与市场持平\"，目标价微调至113美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133871627","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133871627?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:08","pubTimestamp":1770034113,"startTime":"0","endTime":"0","summary":"投资机构Leerink Partners宣布将BioNTech SE（BNTX）的股票评级从\"跑赢大盘\"下调至\"与市场持平\"。与此同时，该机构将其目标股价从112.00美元小幅上调至113.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4551","BNTX","BK4535","BK4588","BK4568","BK4139","BK4585"],"gpt_icon":0},{"id":"2605823476","title":"Biontech Se盘中异动 早盘大幅上涨5.00%报123.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605823476","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605823476?lang=zh_cn&edition=full","pubTime":"2026-01-22 23:11","pubTimestamp":1769094702,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日23时11分，Biontech Se股票出现波动，股价快速拉升5.00%。截至发稿，该股报123.90美元/股，成交量53.427万股，换手率0.21%，振幅3.97%。Biontech Se股票所在的生物技术行业中，整体涨幅为1.03%。Biontech Se公司简介：BioNTech是一家总部位于德国的生物技术公司，专注于开发癌症治疗药物，包括个体化免疫疗法，以及包括新冠病毒在内的传染病疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122231142a44a7757&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122231142a44a7757&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4551","BNTX","BK4585","BK4588","BK4535","BK4568","BK4548"],"gpt_icon":0},{"id":"1126740215","title":"BioNTech预计未来五年将公布至少17项晚期临床试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1126740215","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126740215?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:08","pubTimestamp":1768219728,"startTime":"0","endTime":"0","summary":"BioNTech SE宣布，在接下来五年内，预计将从处于晚期开发阶段的临床试验中发布至少17项数据成果。在肿瘤治疗领域，该公司计划于2026年启动另外6项三期临床试验。若临床试验数据呈现积极结果，BioNTech有望在2030年前发展成为拥有多款肿瘤产品的企业。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4548","BK4585","BK4588","BNTX","BK4568","BK4535","BK4139"],"gpt_icon":0},{"id":"2602553921","title":"BioNTech、辉瑞大举进攻，PD-(L)1/VEGF双抗开始分化了","url":"https://stock-news.laohu8.com/highlight/detail?id=2602553921","media":"氨基观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602553921?lang=zh_cn&edition=full","pubTime":"2026-01-11 13:39","pubTimestamp":1768109940,"startTime":"0","endTime":"0","summary":"文｜氨基观察1月6日，美国Instil Bio宣布，其子公司Axion Bio决定终止与宜明昂科此前达成的合作协议，涉及PD-L1/VEGF双抗AXN-2510以及CTLA-4单抗AXN-27M。消息公布当日，Instil Bio股价暴跌53%，回落至交易前水平。尤其是随着PD-1+ADC的疗效被反复验证后，PD-1/VEGF双抗的联用正迅速铺开。/ 03 /分化开始AXN-2510的“退货”开启了PD-1/VEGF赛道的分化。截至目前，全球范围内PD-1/VEGF双抗的项目已超过40个，其中国内就有20余款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111134716a70cd852&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111134716a70cd852&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0058720904.USD","IE00B19Z3B42.SGD","BK4023","SG9999001176.SGD","BK4550","LU0225284248.USD","BK4585","LU1066051498.USD","IE00BLSP4239.USD","BK4592","IE00BLSP4452.SGD","BK4107","BK4581","BK4588","LU1169590202.USD","IE000M9KFDE8.USD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0053666078.USD","LU0306806265.USD","LU1023059063.AUD","SG9999013999.USD","LU1066053197.SGD","LU0985481810.HKD","SG9999002224.SGD","LU0321505439.SGD","LU0122379950.USD","LU0225771236.USD","BNTX","LU0456855351.SGD","LU0170899867.USD","LU0868494617.USD","BK4599","PFE","LU0234572021.USD","LU1057294990.SGD","BK4568","BK4533","SG9999003800.SGD","IE0002270589.USD","LU1169589451.USD","BK4007","LU0306807586.USD","LU1883839398.USD","LU1894683348.USD","SG9999001176.USD","SG9999002232.USD","LU0321505868.SGD","BK4534","IE00B19Z3581.USD","LU0210528500.USD","LU1894683264.USD","LU2487616109.SGD","LU0289739699.SGD","SG9999011175.SGD"],"gpt_icon":1},{"id":"1196264094","title":"BioNTech完成对CureVac的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1196264094","media":"投资观察","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196264094?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:14","pubTimestamp":1766052856,"startTime":"0","endTime":"0","summary":"12月18日 - BioNTech SE宣布已完成对CureVac B.V.的收购，约86.75%的CureVac股份已被拍卖。CureVac将继续按照现有的业务流程运营，并将完成必要的分析，以确定未来的组织和投资组合结构。预计在2026年1月将强制收购剩余股份。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVAC","BK4588","BK4535","BK4568","BNTX","BK4548","BK4585","BK4551","BK4139"],"gpt_icon":0},{"id":"1103967501","title":"Biontech与施贵宝公布Pumitamig全球二期研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1103967501","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103967501?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:18","pubTimestamp":1765282713,"startTime":"0","endTime":"0","summary":"12月9日（路透社）- BioNTech SE与施贵宝首次公布PD-L1XVEGF-A双特异性抗体Pumitamig在晚期三阴性乳腺癌中的全球二期研究数据，显示出令人鼓舞的疗效。Pumitamig联合化疗实现了61.5%的确认客观反应率、71.8%的未确认客观反应率和92.3%的疾病控制率，与PD-L1表达水平无关。这些数据与先前在中国进行的1L TNBC I期/II期临床试验中报告的数据一致，并确认了关键III期ROSETTA BREAST-01试验的剂量选择。相关数据将于2025年圣安东尼奥乳腺癌研讨会上公布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0985481810.HKD","LU2133065610.SGD","LU0237698245.USD","BK4532","LU0096364046.USD","LU2125154935.USD","LU1670711040.USD","IE00BJJMRZ35.SGD","BK4551","LU1430594728.SGD","IE0009355771.USD","LU1074936037.SGD","LU1989771016.USD","BK4559","BK4568","IE0002141913.USD","IE00B2B36J28.USD","LU1868836591.USD","BK4581","BK4548","IE00BFTCPJ56.SGD","LU0267386448.USD","LU1670710588.SGD","BK4585","LU0456855351.SGD","LU1868837136.USD","LU2242652126.USD","BK4139","LU0061475181.USD","LU1718418525.SGD","LU1093756325.SGD","LU1261432733.SGD","LU0225284248.USD","BMY","IE00BFXG1179.USD","LU1670710661.SGD","LU1093756168.USD","BK4588","LU1868837300.USD","LU2125154778.USD","BK4535","BK4534","LU1868836914.USD","IE00BJT1NW94.SGD","LU0306806265.USD","LU0321505868.SGD","LU2242646821.SGD","LU0321505439.SGD","LU1291159041.SGD","LU1585245621.USD","LU1868836757.USD","LU0882574055.USD","LU1032466523.USD","LU0225771236.USD","LU1670711123.USD","LU2360032135.SGD","LU0114720955.EUR","IE00BSNM7G36.USD","LU1571399168.USD","LU1323610961.USD","LU0868494617.USD","BNTX","LU0306807586.USD"],"gpt_icon":0},{"id":"1183793255","title":"异动解读 | BioNTech夜盘大涨6.22%，因肺癌药物GOTISTOBART获显著临床成果及FDA快速通道认证","url":"https://stock-news.laohu8.com/highlight/detail?id=1183793255","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183793255?lang=zh_cn&edition=full","pubTime":"2025-12-08 15:08","pubTimestamp":1765177718,"startTime":"0","endTime":"0","summary":"BioNTech SE（BNTX）今日夜盘大涨6.22%，市场反应积极。消息面上，BioNTech与OncoC4宣布，其选择性Treg调节剂GOTISTOBART在既往治疗的鳞状非小细胞肺癌患者中显示出临床上有意义的总体生存益处。该药物在降低死亡风险方面超过标准化疗超过一半，并已获得美国食品药品监督管理局（FDA）的快速通道认证。此外，在GOTISTOBART治疗组中，报告的≥3级治疗相关不良事件（AE）为19/45（42.2%），而多西他赛治疗组为20/41（48.8%）。这一积极数据增强了市场对BioNTech未来业绩的乐观预期，推动了股价上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BNTX"],"gpt_icon":0},{"id":"1100346533","title":"Biontech与OncoC4宣布肺癌药物显著改善总体生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1100346533","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100346533?lang=zh_cn&edition=full","pubTime":"2025-12-08 15:06","pubTimestamp":1765177604,"startTime":"0","endTime":"0","summary":"12月8日（路透社） - BioNTech表示，*BIONTECH与ONCOC4宣布选择性Treg调节剂GOTISTOBART在既往治疗的鳞状非小细胞肺癌患者中显示出临床上有意义的总体生存益处*GOTISTOBART在降低死亡风险方面超过标准化疗超过一半*GOTISTOBART已获得美国食品药品监督管理局（“FDA”）的快速通道认证*在GOTISTOBART治疗组中，报告的≥3级治疗相关不良事件（“AE”）为19/45（42.2%），而多西他赛治疗组为20/41（48.8%）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4139","BK4551","BNTX","BK4548","BK4585","BK4588","BK4568"],"gpt_icon":0},{"id":"1186165748","title":"美股疫苗股大跌，FDA 官员提及新冠疫苗与年轻男性心脏疾病有关联","url":"https://stock-news.laohu8.com/highlight/detail?id=1186165748","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186165748?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:25","pubTimestamp":1764635137,"startTime":"0","endTime":"0","summary":"在疫情期间，Prasad 因反对疫苗强制措施以及对新冠疫苗引发心肌炎风险的关注而在网上获得追随者。其他研究则发现，新冠感染导致心肌炎的风险高于接种疫苗。辉瑞和 BioNTech 共同研发了新冠疫苗 Comirnaty。两家公司均研发并销售新冠 mRNA 疫苗。这并非 Prasad 首次推动与 mRNA 新冠疫苗相关的变更。这位 FDA 官员还呼吁为疫苗临床试验设定不同的终点指标。","market":"us","thumbnail":"https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f5a0c542474fbfdd95db309645c9c3a7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"美股疫苗股大跌，FDA 官员提及新冠疫苗与年轻男性心脏疾病有关联","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE","MRNA","DVAX","BNTX"],"gpt_icon":1},{"id":"1152494916","title":"异动解读 | FDA提及儿童死亡与新冠疫苗关联，BioNTech盘中大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152494916","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152494916?lang=zh_cn&edition=full","pubTime":"2025-12-02 03:10","pubTimestamp":1764616233,"startTime":"0","endTime":"0","summary":"BioNTech SE (BNTX) 今日盘中大跌5.02%，引发了市场的广泛关注。消息面上，美国食品药品管理局（FDA）的一份备忘录提及儿童死亡与新冠疫苗的关联，导致疫苗股普遍下跌。BioNTech作为新冠疫苗的主要生产商之一，股价受到直接影响。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f5a0c542474fbfdd95db309645c9c3a7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BNTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biontech.com","stockEarnings":[{"period":"1week","weight":-0.0849},{"period":"1month","weight":-0.2119},{"period":"3month","weight":-0.0865},{"period":"6month","weight":-0.1149},{"period":"1year","weight":-0.1374},{"period":"ytd","weight":-0.0881}],"compareEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0526},{"period":"3month","weight":-0.0539},{"period":"6month","weight":-0.0074},{"period":"1year","weight":0.1378},{"period":"ytd","weight":-0.0421}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioNTech SE成立于2008年6月2日。该公司结合了数十年的免疫学，尖端治疗平台以及各种患者分析和生物信息学工具的开创性研究，开发针对癌症和其他疾病的个体化免疫疗法。该公司利用强大的新治疗机制，利用各种生物学靶点，利用每位患者免疫系统的力量，解决每位患者潜在疾病的独特分子特征。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.014337},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.037906},{"month":3,"riseRate":0.571429,"avgChangeRate":0.055005},{"month":4,"riseRate":0.333333,"avgChangeRate":0.062444},{"month":5,"riseRate":0.666667,"avgChangeRate":0.046025},{"month":6,"riseRate":0.666667,"avgChangeRate":0.049136},{"month":7,"riseRate":1,"avgChangeRate":0.149272},{"month":8,"riseRate":0.5,"avgChangeRate":-0.051873},{"month":9,"riseRate":0.333333,"avgChangeRate":0.020492},{"month":10,"riseRate":0.666667,"avgChangeRate":0.023565},{"month":11,"riseRate":0.857143,"avgChangeRate":0.192937},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.033371}],"exchange":"NASDAQ","name":"BioNTech SE","nameEN":"BioNTech SE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioNTech SE,BNTX,BioNTech SE股票,BioNTech SE股票老虎,BioNTech SE股票老虎国际,BioNTech SE行情,BioNTech SE股票行情,BioNTech SE股价,BioNTech SE股市,BioNTech SE股票价格,BioNTech SE股票交易,BioNTech SE股票购买,BioNTech SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}